Following prolonged treatment with ARSIs, a smaller subset of patients with CRPC go on to develop other driver mutations and no longer rely on AR signaling, a subcategory of highly lethal PCa variants termed androgen-indifferent PCa (AIPC) where effective treatments are lacking [13]. This evidence concerns the gene AR and posterior cortical atrophy.